News
-
- 06.02 2026
-
Breaking News| First-in-Human Clinical Study of BristarImmunotech’s Dual-Epitope Anti-LILRB4 STAR‑T Published
Recently, the first-in-human clinical research paper regarding dual-epitope anti-LILRB4 STAR‑T for relapsed/refractory acute myeloid leukemia (R/R AML), jointly completed by BristarImmunotech, Peking University People’s Hospital and School of Basic Medical Sciences, Tsinghua University, has been formally accepted for publication by Signal Transduction and
-
- 05.29 2026
-
Press Preview| BristarImmunotech to Present Clinical Data of Off-the-Shelf Universal STAR-T at EULAR 2026
The Annual Congress of the European Alliance of Associations for Rheumatology (EULAR), one of the world’s top authoritative academic conferences in rheumatology and immunology, is set to kick off shortly. BristarImmunotech will present clinical findings of its universal CD19 STAR-T (YTS109) for severe/refractory autoimmune diseases via an abstract presentation, showcasing
-
- 04.20 2026
-
AACR Annual Meeting | BriSTAR Immunotech's Presents Clinical Progress of GPC3-Targeted STAR-T Cell Therapy at AACR 2026
Recently, the 2026 Annual Meeting of the American Association for Cancer Research (AACR), a globally influential academic event in oncology, was successfully held in San Diego, California, USA. Following the presentation of LILRB4-targeted STAR-T research data at AACR 2023, Sinocelltech once again made a major appearance on this top international academic stage. This
-
- 08.29 2025
-
Nature Medicine Publishes a Breakthrough! Experts highly praise
A major step forward for off-the-shelf cell therapy in autoimmunity. Prof. Huji Xu, Prof. Xin Lin, and BriSTAR Immunotech are breaking new ground with YTS109, a hypoimmune allogeneic T cell product. Published in Nature Medicine:
-
- 08.28 2025
-
Landmark Study Published in Nature Medicine: BriSTAR Immunotech’s Allogeneic STAR-T Breaks New Ground in Refractory Lupus Nephritis Treatment
On August 27, 2025, a groundbreaking study by BriSTAR Immunotech in collaboration with the team led by Professor Huji Xu and Professor Xin Lin , was published in the top international journal Nature Medicine (Impact Factor: 58.7).
-
- 11.18 2024
-
Professor Xin Lin's Team Publishes Landmark Research in Cell Sub-Journal: STAR-T Technology Enables Targeting of Intracellular Neoantigens for Solid Tumor Therapy
Recently, a team led by Professor Xin Lin — Scientific Founder of Bristar Immunotech and Tenured Professor at Tsinghua University — published a research article titled "TCR-mimicking STAR conveys superior sensitivity over CAR in targeting tumors with low-density neoantigens" in Cell Reports, a sub-journal of Cell. This study demonstrates the high sensitivity of the novel chimeric antigen receptor STAR-T in targeting tumors with low-abundance neoantigens, promising to advance T-cell immunotherapy into an era of greater precision and efficacy. It also marks another breakthrough in STAR-T technology research.
-
- 03.23 2023
-
BriSTAR Immunotech to Present its Novel Cell Therapy for Acute Myeloid Leukemia at the 2023 AACR Annual Meeting
March 23, 2023 - TORONTO & BEIJING -- BriSTAR Immunotech, a clinical-stage cell therapy company, announced today it will showcase its T-cell receptors (TCR) and antigen receptor (STAR)-T cell therapy platform at the American Association for Cancer Research (AACR) Annual Meeting, taking place from April 14-19, 2023 in Orlando, Florida.
-
- 01.31 2023
-
BriSTAR Immunotech to Present at the BIO CEO & Investor Conference
January 31, 2023 - TORONTO & BEIJING -- BriSTAR Immunotech, a clinical-stage cell therapy company, announced today that its Chief Executive Officer, James Pan, Ph.D., will be presenting at the 25th BIO CEO & Investor Conference. The conference will take place at the New York Marriott Marquis during February 6-9, 2023.
-
- 01.19 2023
-
BriSTAR Immunotech To Present its Novel Cell Therapy for Acute Myeloid Leukemia at the AACR Special Conference on AML and MDS
January 19, 2023 - TORONTO & BEIJING -- BriSTAR Immunotech, a clinical-stage cell therapy company, announced today it will showcase its T-cell receptors (TCR) and antigen receptor (STAR)-T cell therapy technology platform at the American Association for Cancer Research (AACR) special conference on acute myeloid leukemia and myelodysplastic syndrome, taking place January 23-25, 2023, in Austin, Texas.
-
- 09.19 2023
-
BriSTAR Immunotech Announces the Addition of Dr. Christopher J. Paige as a Member of the Company's Scientific Advisory Board
On September 19, 2022 - TORONTO & BEIJING -- BriSTAR Immunotech announced that Dr. Christopher J. Paige, a world-renowned leader in the field of lymphocyte development and antibody formation and an expert in immunotherapy, has joined the company's Scientific Advisory Board.